167 related articles for article (PubMed ID: 27225050)
21. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
Hori Y; Matsukawa J; Takeuchi T; Nishida H; Kajino M; Inatomi N
J Pharmacol Exp Ther; 2011 Jun; 337(3):797-804. PubMed ID: 21411494
[TBL] [Abstract][Full Text] [Related]
22. Disposition of the new antirheumatic agent ethyl 4-(3,4-dimethoxyphenyl)- 6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) in rats and dogs.
Tagawa Y; Kiyota Y; Yoshimura Y; Motohashi M; Tanayama S
Arzneimittelforschung; 1998 Jul; 48(7):750-7. PubMed ID: 9706376
[TBL] [Abstract][Full Text] [Related]
23. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
Prakash C; Soliman V
Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of 4-acetylaminophenylacetic acid. 1st communication: absorption, distribution, metabolism and excretion in mice, rats, dogs and monkeys after single administration of 14C-labeled compound.
Sugihara K; Morino A; Nomura A; Iida S; Sugiyama M
Arzneimittelforschung; 1990 Jul; 40(7):800-5. PubMed ID: 2222556
[TBL] [Abstract][Full Text] [Related]
27. Disposition and metabolism of finasteride in dogs.
Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.
Michiels M; Monbaliu J; Meuldermans W; Hendriks R; Geerts R; Woestenborghs R; Heykants J
Arzneimittelforschung; 1988 Jun; 38(6):775-84. PubMed ID: 3178917
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
Sugimoto T; Hayashi T; Okita A; Morino A
Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
[TBL] [Abstract][Full Text] [Related]
30. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
[TBL] [Abstract][Full Text] [Related]
31. Investigation of disposition for TAK-448, a synthetic peptide of kisspeptin analog, in rats and dogs using the radiolabeled TAK-448 suitable for pharmacokinetic study.
Moriya Y; Kogame A; Tagawa Y; Morohashi A; Kondo T; Asahi S
Xenobiotica; 2019 Jul; 49(7):833-839. PubMed ID: 30044673
[TBL] [Abstract][Full Text] [Related]
32. Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs.
Sasaki H; Kamimura H; Shiobara Y; Esumi Y; Takaichi M; Yokoshima T
Xenobiotica; 1982 Dec; 12(12):803-12. PubMed ID: 7170790
[TBL] [Abstract][Full Text] [Related]
33. The pharmacokinetics of nitrendipine. I. Absorption, plasma concentrations, and excretion after single administration of [14C]nitrendipine to rats and dogs.
Krause HP; Ahr HJ; Beermann D; Siefert HM; Suwelack D; Weber H
Arzneimittelforschung; 1988 Nov; 38(11):1593-9. PubMed ID: 3214442
[TBL] [Abstract][Full Text] [Related]
34. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans.
Dalvie D; Cosker T; Boyden T; Zhou S; Schroeder C; Potchoiba MJ
Drug Metab Dispos; 2008 Sep; 36(9):1869-83. PubMed ID: 18566038
[TBL] [Abstract][Full Text] [Related]
35. Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.
Waters NJ; Smith SA; Olhava EJ; Duncan KW; Burton RD; O'Neill J; Rodrigue ME; Pollock RM; Moyer MP; Chesworth R
Cancer Chemother Pharmacol; 2016 Jan; 77(1):43-62. PubMed ID: 26645404
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine.
Ahr HJ; Krause HP; Siefert HM; Suwelack D; Weber H
Arzneimittelforschung; 1988 Aug; 38(8):1093-8. PubMed ID: 3196402
[TBL] [Abstract][Full Text] [Related]
37. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
[TBL] [Abstract][Full Text] [Related]
38. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
Yue Q; Chen YH; Mulder T; Deese A; Takahashi R; Rudewicz PJ; Reynolds M; Solon E; Hop CE; Wong H; Khojasteh SC
Drug Metab Dispos; 2011 Jun; 39(6):952-65. PubMed ID: 21363998
[TBL] [Abstract][Full Text] [Related]
39. Investigation of the unique metabolic fate of ethyl (6R)-6- [N- (2-chloro-4-fluorophenyl) sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242) in rats and dogs using two types of 14C-labeled compounds having different labeled positions.
Jinno F; Kakehi M; Takeuchi T; Tagawa Y; Kondo T; Asahi S
Arzneimittelforschung; 2011; 61(8):458-71. PubMed ID: 21950150
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
